2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact, adherence challenges, and nursing management

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care

ASCO 2026: Highlights and analysis

Bupropion shows benefit for cancer-related fatigue in cancer survivors

Aspirin in stage III colorectal cancer shows no significant DFS benefit but favourable safety

ASCO 2026: Latest in prostate cancer

Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo

GLP-1 therapy associated with reduced breast cancer risk

Gene expression test guided therapy in ER+/HER2- early breast cancer allows safe chemotherapy omission

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

GLP-1 use linked to improved survival in patients with cancer

Darovasertib plus crizotinib improves outcomes in HLA-A2–negative metastatic uveal melanoma